1. Generics Bulletin
  2. >>Business
  3. >>Deals

Torrent buys way into controlled substances

Torrent Pharmaceuticals has ventured into the US controlled substances sector by paying an undisclosed fee for local generics and OTC player Bio-Pharm Inc (BPI). “This acquisition is an important step for increasing Torrent’s presence in the US, is consistent with our strategy of dosage-form diversification, and provides us with new capabilities, including manufacturing and research and development presence in the US,” the Indian company commented.

Torrent Pharmaceuticals has ventured into the US controlled substances sector by paying an undisclosed fee for local generics and OTC player Bio-Pharm Inc (BPI). “This acquisition is an important step for increasing Torrent’s presence in the US, is consistent with our strategy of dosage-form diversification, and provides us with new capabilities, including manufacturing and research and development presence in the US,” the Indian company commented.

“Established in 1992,” Torrent explained, “BPI has a proven track record in the research, development and manufacturing of oral solutions,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By Dave Wallace

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By Dave Wallace

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.

Polpharma Biologics And Fresenius Kabi Team Up On Entyvio Biosimilar

 
• By Urtė Fultinavičiūtė

Fresenius Kabi has picked up commercialization rights to Polpharma Biologics’ vedolizumab biosimilars in almost all markets. Still, the originator Takeda stands solid with no competition expected until at least 2032.

More from Business

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By Dave Wallace

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By Dave Wallace

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.